With the widespread use of antiretroviral therapy (ART), hospitalization rates, length of stay, and morbidity and mortality have dramatically declined among patients infected with human immunodeficiency virus (HIV) \[[@OFU010C1]--[@OFU010C10]\]. The causes of hospitalization and death in regions where ART is available have shifted from predominantly acquired immune deficiency syndrome (AIDS)-defining opportunistic infections to non-AIDS-related comorbidities \[[@OFU010C1], [@OFU010C2], [@OFU010C4]--[@OFU010C7], [@OFU010C9], [@OFU010C10]\].

Despite a recent reduction in the number of HIV infections attributed to injected drug use in developed countries, drug users still represent a large proportion of individuals living with HIV infection in the era of ART \[[@OFU010C11]\] and continue to have disproportionately high hospitalization rates compared with other HIV categories \[[@OFU010C1], [@OFU010C3], [@OFU010C7], [@OFU010C8], [@OFU010C12]\]. Late HIV diagnosis, low CD4 counts, and not receiving ART drugs and comorbidities are strong predictors of hospitalization among HIV-positive intravenous drug users (HIV-IDU) \[[@OFU010C2], [@OFU010C3], [@OFU010C5], [@OFU010C8]--[@OFU010C10], [@OFU010C12]\].

However, for HIV-IDU, the causes of hospitalization in the late ART era are less well defined, and whether the use of ART has been able to change the causes of hospital admission in the same way as in the non-drug user HIV population remains unclear.

It should be noted that hospitalizations have become a major outcome measure and constitute a considerable component of excess healthcare costs in this special population \[[@OFU010C3], [@OFU010C13], [@OFU010C14]\]. Thus, analyzing the clinical characteristics of admitted patients is a useful strategy to assess the effectiveness of health programs and provide areas of interest to improve healthcare to HIV-IDU.

Therefore, the aim of this study was to examine ART use, HIV-1 RNA suppression, and hospital discharge diagnoses among HIV-IDU admitted to an urban hospital in the late ART era.

MATERIAL AND METHODS {#s2}
====================

A retrospective analysis was undertaken in HIV-IDU admitted for the first time to the Infectious Diseases Unit of The Hospital del Mar from January 2006 to December 2010. The Hospital del Mar is a large tertiary teaching hospital, located in the old part of the city of Barcelona (Spain). The catchment area consists mainly of old buildings, the unemployment rate is high, and there is an overrepresentation of immigrants, people with legal problems, drug trafficking, and commercial sex. The Infectious Diseases unit has 20 beds.

Human immunodeficiency virus-positive IDU aged 18 years or older residing in the hospital area of influence and who had injected an illegal drug in the previous 6 months were included in the study. Human immunodeficiency virus-positive IDU admitted to other hospital services for surgical, obstetric, or mental causes (except HIV-associated neurocognitive disorder) were excluded.

Specialized HIV care, including ART, treatment of substance use disorders, and hospitalization are guaranteed free of cost through Spanish Health System for HIV-IDU.

Demographics and clinical characteristics (CD4 cell count, presence or absence of an AIDS diagnosis, usage of ART, date of hospital admission, discharge diagnosis, and outcomes) were obtained directly from the HIV-infected patient database of the Medical Documentation Service of the Hospital for each patient infected with HIV.

Antiretroviral therapy was defined as a combination of at least 3 drugs from 2 or more classes of antiretroviral agents. On admission, patients were classified as either ART-naive, current ART users, or dropouts (patients who had been on ART but had discontinued the medication more than 1 month before admission).

The International Classification of Diseases (ICD-9 and ICD-10) was used to determine hospital discharge diagnosis. For more than 1 diagnosis, the primary diagnosis leading to hospitalization was used. To characterize causes associated with hospitalizations over the 5-year period, the diagnoses were grouped for analysis as follows: AIDS opportunistic infections, malignancies, chronic end-organ damage (vascular, liver, kidney, lung), nonopportunistic infections, and complications derived from injected drug use (overdose, soft tissue infections, and bacteriemia).

Descriptive statistics were expressed as mean, standard deviation, median and range for quantitative variables, and absolute frequencies and percentages for qualitative variables. The χ^2^ or nonparametric tests were applied. Values from *P* \< .05 were considered statistically significant. Statistical analysis was made with SPSS version 15.0 (SPSS, Chicago, IL).

RESULTS {#s3}
=======

Over the 5-year period, 197 HIV-IDU were hospitalized and 78 (39.6%) patients were readmitted, yielding a total of 375 admissions; this figure represents 14.9% (375 of 2518) of the total admissions to the Infectious Disease Unit.

The clinical characteristics of HIV-IDU admitted to the unit are shown in Table [1](#OFU010TB1){ref-type="table"}. Table 1.Clinical Characteristics of HIV-Infected Drug Users Admitted to HospitalPatients no.197Number of patients readmitted (%)78 (39.6%)Number of hospitalizations per person (median, range)1.3 ([@OFU010C1]--[@OFU010C6])Age (mean + SD)40.6 ± 7Male no. (%)134 (68%)Origin no. (%)Spanish173 (87.8%)Non-Spanish24 (12.2%)Main drug dependency no. (%)Heroin 168 (85.7%)Cocaine 29 (14.7%)Treatment of substance use disorder no. (%)158 (80.2%)CDC stage no. (%) A47 (23.9%) B73 (37.1%) C77 (39%)Hepatitis C coinfection no. (%)193 (98%)CD4 count (cells/μL) (median, range)327.98 (8--1086)CD4 count \<200 (cells/μL) no. (%)58 (29.4%)CD4 count 200--350 (cells/μL) no. (%)65 (33.0%)CD4 count \>350 (cells/μL) no. (%)74 (37.6%)ART use at admission no. (%)Current use99 (50.2%)Dropouts65 (33.0%)Naive33 (16.8%)HIV-1 RNA \<50 copies/mL no. (%)75 (38.1%)[^1]

Substance use disorders were treated in 80% of HIV-IDU at an outpatient center. Lifetime prevalence of ART use was 83.2% (164 of 197) and prevalence of ART use at admission was 50% (99 of 197). Antiretroviral therapy at admission was currently used in 61.3% (97 of 158) of patients receiving treatment of substance use disorders versus 5.1% (2 of 39) who were not (*P* \< .000). Reasons for not using ART at admission were dropouts from ART in 66.3% (65 of 98) and naive to ART in 33.7% (33 of 98).

Complete viral suppression was observed in 38.1% (75 of 197) of patients. These patients had a higher median CD4 cell count (442 vs 209 cells/μL; *P* \< .01) and CD4 cell count **\>** 350 cells/μL (62 of 75 \[82.6%\] vs 12 of 122 \[9.8%\]; *P* \< .000) than patients who had HIV-1 RNA detectable viral load.

Hospital discharge diagnoses are shown in Table [2](#OFU010TB2){ref-type="table"}. Bacterial infections were the leading cause of hospitalization, mainly bacterial pneumonia, followed by chronic end-organ damage and complications of injected drug use. Acquired immune deficiency syndrome-defining illnesses were diagnosed in 27 of 197 (13.6%) HIV-IDU (6.6% AIDS opportunistic infections, 5.5% recurrent pneumonia, and 1.5% AIDS malignancies). Table 2.Hospital Discharge Diagnoses Among HIV-Infected Intravenous Drug Users, and Etiologies of Hospitalization Among HIV-Intravenous Drug UsersGroups of CausesDiagnosesNo. (%)EtiologiesNo.Bacterial infectionsPneumonia70 (35.5%)*Streptococcus pneumoniae*47*Haemophilus influenzae*6Nonfiliated17Enteric infections15 (7.7%)*Salmonella* sp7*Escherichia coli*5*Campylobacter jejuni*3Urinary tract infections8 (4.0%)*E coli*6Meningitis4 (2.0%)*S pneumoniae*3*Neisseria meningitidis*1Chronic end-organ damageHepatitis C21 (10.7%)Decompensated cirrhosis21Cardiovascular disease9 (4.6%)Chronic heart failure9Kidney disease3 (1.5%)Acute nephritis3Complications of IDUSoft tissue infections/bacteriemia21 (10.7%)Cellulitis17Endocarditis3Osteomyelitis1Overdose12 (6.1%)Overdose12MalignanciesNon-AIDS malignancies15 (7.5%)Lung9Colorectal3Breast2Hodgkin\'s lymphoma1AIDS-malignancies3 (1.5%)Non-Hodgkin\'s lymphoma3AIDS opportunistic infectionsAIDS opportunistic infections13 (6.6%)*Pulmonary tuberculosis*6*Pneumocystis*4*jirovecii Cerebral toxoplasmosis*2*Esophageal candidiasis*1ART secondary effectsART secondary effects3 (1.5%)Anemia zidovudine2Acute renal failure tenofovir1[^2] Table 3.Groups of Causes of Inpatient Hospitalization Among HIV-Infected Drug UsersGroups of CausesTotal Group No. (%)HIV-1 RNA 50 \< Copies/mL No. (%)HIV-1 RNA 50 \> Copies/mL No. (%)*P*Bacterial infections97 (59.2%)31 (41.3%)66 (54.1%).081Chronic end-organ damage33 (16.8%)27 (36.0%)6 (4.9%).0000Complications derivates of IDU33 (16.%)4 (5.3%)29 (23.8%).0008Malignancies18 (9.1%)12 (12.0 %)6 (7.4%).277AIDS opportunistic infections13 (6.6%)2 (1.3%)12 (9.8%).019HAART secondary effects3 (1.5%)3 (4.0%)0 (0.0%).026[^3]

Causes of inpatient hospitalization according to HIV-1 RNA suppression are shown in Table [3](#OFU010TB3){ref-type="table"}. Patients with HIV-1 RNA \<50 copies/mL were admitted for chronic end-organ damage, particularly for complications of hepatitis C (20.0% vs 2.5%; *P* \< .000). In contrast, patients who had a detectable viral load HIV-1 RNA viral load were admitted for complications derived from injected drug use and opportunistic infections.

Hospital readmissions were observed in 39.6% (78 of 197) of patients. Risk factors for readmission were as follows: HIV-1 RNA \>50 copies/mL (odds ratio \[OR\], 4.8; 95% confidence interval \[CI\], 2.4--9.4; *P* \> .0001), CD4 cell count \>350 cells (OR, 3.6; 95%CI, 1.9--6.8; *P* \> .0001), and women (OR, 2.1; 95% CI, 1.1--4.0; *P* \> .03). Causes of readmissions were as follows: bacterial infections, 95 of 178 (53.3%); injected drug use-related complications, 49 of 178 (27.5%); chronic end-organ damage, 26 of 178 (14.6%); and AIDS opportunistic infections, 8 of 178 (4.5%). No patient died in the study period.

DISCUSSION {#s4}
==========

The results of this study show that HIV-IDU admitted to hospital were not in an advanced stage of HIV infection, and the most common causes of hospitalization were related to non-AIDS illnesses. Nevertheless, HIV-infected intravenous drug users were often readmitted.

A leading factor in reducing the hospital admission rate for both HIV-related and non-HIV-related illnesses is the use of ART \[[@OFU010C2], [@OFU010C4], [@OFU010C5], [@OFU010C8], [@OFU010C9], [@OFU010C12]\]. In this respect, the present study shows that half of the HIV-IDU were not receiving ART at hospital admission (33% dropouts and 16.8% naive). Although substance abuse treatment leads to greater initiation of ART among HIV-IDU and higher subsequent antiretroviral adherence \[[@OFU010C15]--[@OFU010C19]\], only 61.3% (97 of 158) of patients receiving drug addiction treatment were on ART at admission. In Spain, all patients controlled at drug addiction centers are referred for HIV specialty care, indicating that a subgroup of HIV-IDU enrolled in substance use disorder treatment who are referred for specialized HIV care do not initiate, or discontinue, the appropriate HIV care. Interruptions of HIV treatment during follow-up and losses to follow-up at HIV treatment centers are well documented clinical events among HIV patients who continue to inject drugs \[[@OFU010C20], [@OFU010C21]\].

The rate of successful ART was low at admission in the present study but similar to cohort studies that included active injected drug use \[[@OFU010C19], [@OFU010C22]--[@OFU010C24]\]. This observation implies that adherence interventions should be applied for active drug injectors at the time of ART initiation. In this regard, clinical guidelines and policy recommendations support integrating substance use disorder treatment into HIV medical care \[[@OFU010C25]--[@OFU010C26]\] to facilitate the use of directly observed therapy that sustains treatment adherence and leads to clinically significant improvements in health outcomes \[[@OFU010C27]--[@OFU010C34]\].

Other factors associated with a reduction in hospitalizations rates in HIV patients are a higher nadir and proximal CD4 counts \>350 cells/μL \[[@OFU010C2], [@OFU010C4]--[@OFU010C9]\]. This study revealed that two thirds of patients had CD4 counts \<350 cells/μL. Historically, HIV-IDU started ART with significantly lower CD4^+^ T cell counts, had more advanced HIV disease, and worse immune recovery compared with other HIV groups \[[@OFU010C35]\]. These data emphasize the need for including in specific health programs to achieve immune recovery and successful therapy in HIV-IDU.

The majority of hospitalizations observed were not related to HIV in this study, and it highlights the importance of providers being aware of the management of HIV-related comorbidities and of patients being included in preventive health programs to reduce the probability of hospitalization.

Bacterial pneumonia and other bacterial infections were the most common causes of admission, as described in other HIV-transmission categories \[[@OFU010C36]\]. Pneumococcal vaccination is a reasonable prevention strategy for patients infected with HIV at all stages of immunodeficiency, and efforts should be directed towards improving vaccination levels among HIV-IDU \[[@OFU010C36]\].

Liver disease was the main cause of chronic end-organ damage observed in this study, particularly among patients on ART. However, treatment of hepatitis C virus (HCV) is restricted in drug users owing to their continued use of injected drugs. An alternative is the provision of assessment and treatment via opioid substitution treatment clinics, which has proven to be an effective means of engaging populations with a high HCV prevalence \[[@OFU010C37], [@OFU010C38]\].

Furthermore, unlike non-intravenous drug user HIV patients, skin and soft tissue infections are also common, injection-related complications that lead intravenous drug user to hospitalization. By providing environments in which these patients can receive supervised injection, overdose management, and education, supervised injecting facilities can reduce hospitalization rates for complications of intravenous drug use and support the importance of implementing needle and syringe programs for drug users \[[@OFU010C39]\].

Apart from the limitation of being a cross-sectional study, including the lack of a non-intravenous drug user HIV-positive control group, the study was conducted at a single center, and thus the sample might not be representative of the whole population since the impact of external factors may have significantly affected the admission patterns and demographics of this study population. However, the hospital where the study was conducted is located in one of the areas of the city with a high prevalence of intravenous drug use and immigration, and these findings may be consistent with those of other centers. Furthermore, the study was conducted over an extended period of time.

In summary, HIV-IDU are admitted mainly for non-AIDS-related illnesses in the late ART era; however, current ART use is low and the discontinuation of ART is frequent. To reduce the probability of hospitalization, providers need to be aware of the management of HIV-related comorbidities, especially hepatitis C coinfection, and include patients in preventive health programs. Integrated and multidisciplinary care of the patients infected with HIV-1 should be implemented to achieve successful HIV-1-RNA suppression among HIV-IDU.
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[^1]: Abbreviations: ART, highly active antiretroviral therapy; CDC, Centers for Disease Control and Prevention; HIV, human immunodeficiency virus; SD, standard deviation.

[^2]: Abbreviations: AIDS, acquired immune deficiency syndrome; ART, antiretroviral therapy; HIV, human immunodeficiency virus; IDU, intravenous drug use.

[^3]: Abbreviations: AIDS, acquired immune deficiency syndrome; ART, antiretroviral therapy; HAART, highly active ART; HIV, human immunodeficiency virus; IDU, intravenous drug use.
